IRVING, Texas, Aug. 27, 2012 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL) announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.
"Stem cells are early stage cells, formed primarily in bone marrow that can develop into any type of cell -- heart, brain, or other tissues. Stem cells circulate with the blood, congregating in diseased or damaged tissues, where they replace the injured cells with healthy new cells.
"Stem cells form the body's internal repair and rejuvenation system. Physicians consistently report that a greater number of the body's own adult stem cells results in more effective repair.
"Young people have higher levels of stem cells, and usually recover more quickly from injuries or illness. Beginning in our twenties, our stem cell levels begin a constant decline. However, we can increase our stem cell levels with exercise and healthy nutrition.
"Stem-Kine was developed as optimum nourishment to bone marrow, enabling it to produce more stem cells. In two published studies, Stem-Kine was shown to result in an increase of 50% to 100% in the subject's level of circulating stem cells over a prolonged period of time," stated Clinton Howard, CEO of RBC Life Sciences.
About RBC Life Sciences
Through wholly owned subsidiaries, RBC Life Sciences develops, markets and distributes high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
For Further Information:
Richard S. Jablonski, VP/Finance, CFO
SOURCE RBC Life Sciences, Inc.